过表达带电多泡体蛋白2B基因抑制肾透明细胞癌细胞的增殖

doi:10.12122/j.issn.1673-4254.2025.01.16

摘要/Abstract

摘要：

目的肾透明细胞癌中带电多泡体蛋白2B（CHMP2B）的表达水平与临床病理特征及预后的关系，探究CHMP2B 在肾透明细胞癌发生发展中的潜在作用机制。方法从TCGA数据库下载并整理肾透明细胞癌的RNAseq数据并提取FPKM格式的数据，比较肿瘤样本与癌旁样本 CHMP2B的表达差异，根据其表达中位值分为高、低表达组，分析CHMP2B表达水平与临床病理特征的相关性，采用Kaplan-Meier模型进行生存分析，COX风险回归模型用于临床预后因素分析；使用ESTIMATE算法分析CHMP2B与免疫和基质细胞浸润及肿瘤纯度的关系；使用Limma包对CHMP2B筛选共表达基因，并进一步行GSVA富集分析。使用ESTIMATE算法和Timer数据库分析CHMP2B表达与免疫浸润的相关性；使用cBioPortal数据库分析CHMP2B的基因突变对肾透明细胞癌免疫治疗的影响；从HPA数据库获取CHMP2B蛋白质在肾透明细胞癌组织和正常组织的免疫组化表达情况；通过收集健康与肾癌患者外周血标本评价CHMP2B作为临床标志物的可能。通过细胞实验验证CHMP2B对肾癌细胞增殖与迁移的影响。结果与癌旁组织相比较，CHMP2B在肾透明细胞癌组织中低表达，使其过表达会抑制肿瘤细胞增殖（P<0.01），其表达水平与年龄、性别、是否淋巴结转移以及分期等具有相关性（P<0.05）。生存分析结果显示CHMP2B低表达肾透明细胞癌患者生存预后更差（P<0.05），富集差异分析及共表达基因富集发现CHMP2B 在肾透明细胞癌中主要涉及病毒出芽、坏死性凋亡、内吞作用等，并涉及免疫调节过程。结论 CHMP2B在肾透明细胞癌组织中低表达，可有效影响肿瘤进展和肿瘤免疫过程，是一种有前途的预后分子标志物及治疗靶点。

关键词: 肾透明细胞癌, 带电多泡体蛋白2B, 内体分选复合物, 预后, 免疫

Abstract:

Objective To analyze the association of CHMP2B expression level of with clinicopathological characteristics and prognosis of clear cell renal cell carcinoma (CRCC) and the possible role of CHMP2B in tumorigenesis and progression of CRCC. Methods RNAseq data of CRCC were downloaded from the TCGA database for analysis of CHMP2B expression levels in tumor and adjacent tissues and their correlation with clinicopathological characteristics of the patients. Survival outcomes of the patients with high and low CHMP2B expressions were analyzed using the Kaplan-Meier model, and the COX risk regression model was used for identifying the prognostic factors of the patients. The correlation between CHMP2B expression and immune infiltration, its co-expressed genes, and the effect of CHMP2B gene mutations on immunotherapy responses, and its immunohistochemical expression in CRCC and normal tissues were analyzed. Clinical samples of CRCC were collected to examine CHMP2B expressions using RT-PCR, and cell experiment was carried out to test the effect of CHMP2B overexpression on biological behaviors of CRCC cells. Results CHMP2B was significantly under-expressed in renal cancer tissues, and its overexpression obviously inhibited the proliferation of CRCC cells in vitro. CHMP2B expression level was significantly correlated with age, gender, lymph node metastasis, and tumor stage, and the patients with low CHMP2B expression had poor survival outcomes. Enrichment and co-expression gene analyses suggested that CHMP2B was mainly involved in viral outgrowth, necrotic apoptosis, endocytosis, and immune-regulatory processes in kidney cancer. Conclusion CHMP2B is lowly expressed in renal cancer tissues to affect tumor progression and tumor immune processes, and may serve as a prognostic biomarker and therapeutic target for CRCC.

Key words: renal clear cell carcinoma, charged multivesicular body protein 2B, endosomal sorting complex required for transport, prognosis, immunity

陈晓睿, 魏青政, 张宗亮, 原江水, 宋卫青. 过表达带电多泡体蛋白2B基因抑制肾透明细胞癌细胞的增殖[J]. 南方医科大学学报, 2025, 45(1): 126-136.

Xiaorui CHEN, Qingzheng WEI, Zongliang ZHANG, Jiangshui YUAN, Weiqing SONG. Overexpression of CHMP2B suppresses proliferation of renal clear cell carcinoma cells[J]. Journal of Southern Medical University, 2025, 45(1): 126-136.

图/表 12

图1 CHMP2B在KIRC中的差异表达

Fig.1 Differential expression of CHMP2B in KIRC. A: Unpaired difference analysis. B: Paired difference analysis.

图2 CHMP2B生存分析

Fig.2 CHMP2B survival analysis in CRCC patients. A: CHMP2B ROC curve for predicting overall survival (The x axis is the false positive rate, and the x axis the true positive rate). B: Effect of high and low CHMP2B expression on overall survival of KIRC patients. C: Effect of high and low CHMP2B expression on disease-specific survival of KIRC.

图3 CHMP2B表达与KIRC临床特征的相关性分析

Fig.3 Correlation analysis between CHMP2B expression and clinical characteristics of CRCC patients. A: Relationship between CHMP2B expression and T stage. B: Relationship between CHMP2B expression and N stage. C: Relationship between CHMP2B expression and M stage. D: Relationship between CHMP2B expression and grade. E: Relationship between CHMP2B expression and gender. F: Relationship between CHMP2B expression and age. ***P<0.001.

图4 COX回归分析

Fig.4 COX regression analysis. A: Univariate analysis. B: Multivariate analysis. C: Nomogram of survival rate.

图5 CHMP2B在KIRC中与ESCRT家族相关性分析、GO分析以及KEGG富集分析

Fig.5 CHMP2B was correlated with ESCRT family analysis, GO analysis and KEGG enrichment analysis in KIRC.. A: Relationship between CHMP2B and ESCRT family genes. B: GO analysis of CHMP2B. C: KEGG analysis of CHMP2B.

图6 GSVA富集分析

Fig.6 GSVA enrichment analysis. A: KEGG analysis of CHMP2B. B: GO analysis of CHMP2B.

图7 CHMP2B在泛癌中的差异表达

Fig.7 Differential expression of CHMP2B in pan-cancer. *P<0.05, **P<0.01, ***P<0.001.

图8 CHMP2B与肿瘤微环境相关性分析

Fig.8 Correlation analysis between CHMP2B and tumor microenvironment. A: CHMP2B immune score. B: Relationship between CHMP2B expression and immune cells. C: Differential expression of CHMP2B in immune cells. *P<0.05, **P<0.01, ***P<0.001.

图9 CHMP2B免疫相关分析

Fig.9 CHMP2B immune correlation analysis. A: Heatmap of related immune checkpoint. B: Scatter plot of immune mutation. C: Relationship between high and low CHMP2B expression and treatment with ctla 4 and pd 1.

图10 CHMP2B免疫组化

Fig.10 CHMP2B immunohistochemistry. A: Renal clear cell carcinoma tissue. B: Normal kidney tissue.

图11 RT-PCR分析CHMP2B差异表达

Fig.11 Differential CHMP2B expression analyzed using RT-PCR. ****P<0.0001 vs NC.

图12 CHMP2B对透明细胞癌细胞786-O生物学行为的影响

Fig.12 Effects of CHMP2B on the biological behaviors of clear cell carcinoma cells 786-O. A: Expression level of CHMP2B gene in the transfected cells detected with real-time PCR. B: Change of cell proliferation rate assessed with CCK-8 experiment. C: Effect of overexpression of CHMP2B on horizontal migration ability of the cells (Original magnification: ×100). D: Effect of overexpression CHMP2B on vertical migration ability of cells in Transwell experiment (crystal violet staining, ×100). ****P<0.0001 vs Vector-NC.

参考文献 33

1	陈磊, 徐杰茹, 王冕, 等. 1990-2019年中国肾透明细胞癌死亡趋势及其年龄-时期-队列分析[J]. 中华疾病控制杂志, 2021, 25(9): 1026-33, 1111.
2	张永贞, 杨国庆, 张思维, 等. 中国2009年肾及泌尿系统其他癌发病和死亡分析[J]. 中国肿瘤, 2013, 22(5): 333-7.
3	李凡, 管维. 肾透明细胞癌诊疗相关进展[J]. 临床外科杂志, 2021, 29(2): 101-4.
4	李雁铭, 赵志刚. 肿瘤靶向药物研究进展[J]. 中国药业, 2021, 30(21): 128-34.
5	Ricketts CJ, De Cubas AA, Fan HH, et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma[J]. Cell Rep, 2018, 23(12): 3698.
6	赵广宁, 李黎明. 肾细胞癌临床治疗的新进展[J]. 医学综述, 2021, 27(8): 1545-50.
7	Ha D, Yang NN, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges[J]. Acta Pharm Sin B, 2016, 6(4): 287-96.
8	王敏, 孙倩. 内吞体运输必需分选复合物在肿瘤中的作用[J].中国肿瘤临床, 2023, 50(13): 673-8.
9	李晓康. SIRT6保护衰老心肌减轻缺血再灌注损伤的机制研究[D]. 西安: 中国人民解放军空军军医大学, 2022.
10	Li HY, Ni HL, Li Y, et al. Tumors cells with mismatch repair deficiency induce hyperactivation of pyroptosis resistant to cell membrane damage but are more sensitive to co-treatment of IFN-γ and TNF-α to PANoptosis[J]. Cell Death Discov, 2024, 10(1): 227.
11	Guo Y, Shang A, Wang S, et al. Multidimensional Analysis of CHMP family members in hepatocellular carcinoma[J]. Int J Gen Med, 2022, 15: 2877-94.
12	Motooka Y, Toyokuni S. Ferroptosis as ultimate target of cancer therapy[J]. Antioxid Redox Signal, 2023, 39(1/2/3): 206-23.
13	陈晓睿, 王晓晨, 张宗亮, 等. 基于TCGA数据库探究ESCRT相关基因对膀胱癌的潜在预后价值[J]. 标记免疫分析与临床, 2023, 30(9): 1531-8, 1620.
14	Dai EY, Meng LJ, Kang R, et al. ESCRT-III-dependent membrane repair blocks ferroptosis[J]. Biochem Biophys Res Commun, 2020, 522(2): 415-21.
15	Liu J, Kang R, Tang DL. Signaling pathways and defense mechanisms of ferroptosis[J]. FEBS J, 2022, 289(22): 7038-50.
16	Li J, Belogortseva N, Porter D, et al. Chmp1A functions as a novel tumor suppressor gene in human embryonic kidney and ductal pancreatic tumor cells[J]. Cell Cycle, 2008, 7(18): 2886-93.
17	蔚沐君. AMPK通过CHMP2B调控心肌自噬的机制研究[D]. 延安: 延安大学, 2023.
18	Wu YP, Wu YG, Xu C, et al. CHMP1A suppresses the growth of renal cell carcinoma cells via regulation of the PI3K/mTOR/p53 signaling pathway[J]. Genes Genomics, 2022, 44(7): 823-32.
19	Hu BY, Jiang DW, Chen YY, et al. High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma[J]. Tumour Biol, 2015, 36(4): 2569-81.
20	Gupta N, Sahar T, Khowal S, et al. Differential levels of CHMP2B, LLPH, and SLC25A51 proteins in secondary renal amyloidosis[J]. Expert Rev Proteomics, 2021, 18(1): 65-73.
21	Clayton EL, Milioto C, Muralidharan B, et al. Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown[J]. Brain, 2018, 141(12): 3428-42.
22	Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update[J]. Eur Urol, 2019, 75(5): 799-810.
23	Mei SL, Alchahin AM, Tsea I, et al. Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions[J]. Genome Med, 2024, 16(1): 1.
24	Guo Y, Cui YQ, Li YY, et al. Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer[J]. Cancer Commun, 2023, 43(5): 582-612.
25	魏梦超, 石冰冰, 邢宝坤. 肾透明细胞癌综合诊治的研究进展[J]. 北京医学, 2023, 45(7): 618-22.
26	Bialek J, Yankulov S, Kawan F, et al. Role of nivolumab in the modulation of PD-1 and PD-L1 expression in papillary and clear cell renal carcinoma (RCC)[J]. Biomedicines, 2022, 10(12): 3244.
27	中国抗癌协会泌尿男生殖系肿瘤专业委员会肾癌学组. 晚期肾透明细胞癌一线靶向治疗的优化选择中国专家共识(2022)[J]. 临床泌尿外科杂志, 2022, 37(5): 329-37.
28	Huang Y, Xiong ZY, Wang JJ, et al. Correction to: TBC1D5 reverses the capability of HIF-2 in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy[J]. J Transl Med, 2024, 22(1): 505.
29	Karpova Y, Guo DP, Makhov P, et al. Poly(ADP)-ribosylation inhibition: a promising approach for clear cell renal cell carcinoma therapy[J]. Cancers, 2021, 13(19): 4973.
30	周莉, 盛锡楠. 晚期肾透明细胞癌的治疗规范——《CSCO肾透明细胞癌诊疗指南2020》解读[J]. 肿瘤综合治疗电子杂志, 2020, 6(4): 1-6.
31	陈峰. 靶向联合免疫检查点抑制剂治疗晚期肾透明细胞癌研究进展及单中心初步疗效分析[D]. 济南: 山东大学, 2022.
32	胡青岳, 翟炜, 郑军华. 晚期肾透明细胞癌系统治疗现状与进展[J]. 外科研究与新技术, 2023, 12(4): 237-42.
33	Ugbode C, West RJH. Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotrophic lateral sclerosis[J]. Neurobiol Dis, 2021, 147: 105144.

[1]	罗维, 王宇航, 刘延松, 王媛媛, 艾磊. 高糖环境通过抑制免疫反应基因1的表达诱导巨噬细胞促炎性M1型极化[J]. 南方医科大学学报, 2025, 45(1): 1-9.
[2]	多文娟, 王怡祥, 王家兴, 许鑫龙, 李林献, 杨栋臣, 申启利, 杨立春, 刘晓静, 金启旺, 褚亮, 杨小迪. 重组日本血吸虫半胱氨酸蛋白酶抑制剂可通过调节炎症微环境对“二次打击”脓毒症小鼠发挥治疗作用[J]. 南方医科大学学报, 2025, 45(1): 110-117.
[3]	陈孝华, 鲁辉, 王子良, 王炼, 夏勇生, 耿志军, 张小凤, 宋雪, 王月月, 李静, 胡建国, 左芦根. ABI2在胃癌进展和预后中的作用及其调控机制[J]. 南方医科大学学报, 2024, 44(9): 1653-1661.
[4]	叶梦楠, 武鸿美, 梅琰, 张庆玲. CREM在胃癌中高表达并与患者的不良预后相关[J]. 南方医科大学学报, 2024, 44(9): 1776-1782.
[5]	纪凯, 于冠宇, 周乐其, 张天帅, 凌潜龙, 满文江, 朱冰, 张卫. HNRNPA1基因在结直肠癌组织中高表达及其潜在的诊断和治疗价值[J]. 南方医科大学学报, 2024, 44(9): 1685-1695.
[6]	朱名扬, 王博康, 张秀森, 周克旭, 苗泽宇, 孙江涛. 基线水平CCL19⁺树突状细胞可有效预测肺腺癌患者免疫治疗的敏感性[J]. 南方医科大学学报, 2024, 44(8): 1529-1536.
[7]	陈莉莉, 吴天宇, 张铭, 丁子夏, 张妍, 杨依清, 郑佳倩, 张小楠. 类风湿关节炎的潜在生物标志物及其免疫调控机制：基于GEO数据库[J]. 南方医科大学学报, 2024, 44(6): 1098-1108.
[8]	何欣容, 熊斯丽, 朱真如, 孙景苑, 曹传辉, 王惠. UBE2T通过调节性T细胞诱导肝细胞癌的放疗抵抗[J]. 南方医科大学学报, 2024, 44(6): 1149-1158.
[9]	杨泽, 张秀森, 张旭东, 柳颖, 张嘉诚, 原翔. 基于YTHDF2介导凋亡相关因子降解途径研究牙龈卟啉单胞菌协助食管癌免疫逃逸[J]. 南方医科大学学报, 2024, 44(6): 1159-1165.
[10]	刘鹏程, 娄丽娟, 刘霞, 王建, 姜颖. M2巨噬细胞特征基因风险评分能准确预测HBV相关肝细胞癌患者的预后[J]. 南方医科大学学报, 2024, 44(5): 827-840.
[11]	周伟, 聂军, 胡佳, 蒋艺枝, 张大发. 内质网应激相关基因在主动脉夹层疾病中的差异性表达及与免疫浸润的相关性[J]. 南方医科大学学报, 2024, 44(5): 859-866.
[12]	左志威, 孟庆良, 崔家康, 郭克磊, 卞华. 基于硬皮病线粒体相关基因的人工神经网络模型的构建[J]. 南方医科大学学报, 2024, 44(5): 920-929.
[13]	杨晶晶, 殷丽霞, 段婷, 牛民主, 何震东, 陈心蕊, 张小凤, 李静, 耿志军, 左芦根. 胃癌组织中高表达ATP5A1与患者术后的不良预后和肿瘤细胞的糖代谢有关[J]. 南方医科大学学报, 2024, 44(5): 974-980.
[14]	王沁智, 宋冰, 郝诗睿, 肖志远, 金连辉, 郑通, 柴芳. 基于生物信息学分析CCND2在甲状腺乳头状癌中的表达及其对免疫浸润的影响[J]. 南方医科大学学报, 2024, 44(5): 981-988.
[15]	高志强, 林洁, 洪鹏, 胡再宏, 董军君, 石秦林, 田小毛, 刘丰, 魏光辉. 基于高通量 RNA 测序分析 Wilms 瘤中关键基因对预后及免疫应答的影响[J]. 南方医科大学学报, 2024, 44(4): 727-738.